The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Regulatory News (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.47
Bid: 1.45
Ask: 1.50
Change: -0.04 (-2.64%)
Spread: 0.05 (3.448%)
Open: 1.45
High: 1.47
Low: 1.448
Prev. Close: 1.515
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

17 Nov 2015 15:26

RNS Number : 0501G
Silver Falcon PLC
17 November 2015
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

SILVER FALCON PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Abdelatif LACHAB

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

17/11/2015

6. Date on which issuer notified:

17/11/2015

7. Threshold(s) that is/are crossed orreached: vi, vii

3%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Below 3%

Below 3%

2,300,000

2,300,000

3.54%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

2,300,000

3.54%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

Abdelatif Lachab

15. Contact telephone number:

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLGGGPPGUPAGAM
Date   Source Headline
12th Jun 20197:00 amRNSCDX Effective as Conditioning Therapeutic in vivo
5th Jun 20198:15 amRNSCDX Antibody is Effective against AML in vivo
30th May 20194:40 pmRNSSecond Price Monitoring Extn
30th May 20194:35 pmRNSPrice Monitoring Extension
30th May 20197:00 amRNSCDX Antibody is Effective against ALL in vitro
28th May 20197:00 amRNSPosting of Annual Report and Notice of AGM
15th May 20197:00 amRNSVariation of Terms of Warrant Instrument
1st May 20197:00 amRNSDirector/PDMR Shareholding
29th Apr 20193:10 pmRNSFinal Results for the Year Ended 31 December 2018
30th Jan 20197:00 amRNSPresentation at Cancer Immunotherapy Conference
7th Jan 20197:00 amRNSOperations Update
20th Dec 20187:00 amRNSDirectorate Change
5th Nov 20187:00 amRNSDirectorate Change & Appointment
22nd Oct 20187:00 amRNSOrgenesis collaboration for Hu-PHEC development
19th Oct 20187:00 amRNSCollaboration, License and Investment by Orgenesis
15th Oct 20187:00 amRNSCollaboration with Johnson & Johnson Innovation
28th Sep 20189:30 amRNSHalf-year Report
28th Sep 20187:00 amRNSChange of Adviser
3rd Sep 20187:00 amRNSHemogenyx to present at Oxford conference
27th Jun 201811:39 amRNSResult of AGM
8th Jun 20187:00 amRNSInvestor presentation
5th Jun 20186:05 pmRNSPosting of Annual Report & Notice of AGM
14th May 20187:00 amRNSDevelopment Agreement
8th May 20187:00 amRNSResearch Collaboration with Rockefeller University
30th Apr 20184:23 pmRNSFinal Results
11th Apr 20185:15 pmRNSDirector/PDMR Shareholding
3rd Apr 20187:00 amRNSDirectorate Change
14th Mar 201811:05 amRNSSecond Price Monitoring Extn
14th Mar 201811:00 amRNSPrice Monitoring Extension
13th Mar 20187:00 amRNSCollaboration with major US biotechnology company
6th Mar 20187:00 amRNSAdvisory Board Appointment
1st Mar 20187:00 amRNSAlign Research Initiation of Coverage
27th Feb 20184:40 pmRNSSecond Price Monitoring Extn
27th Feb 20184:35 pmRNSPrice Monitoring Extension
26th Feb 20182:17 pmRNSStmnt re Share Price Movement
12th Feb 20187:00 amRNSDirector/PDMR Shareholding
7th Feb 20187:00 amRNSDirector/PDMR Shareholding
11th Jan 20187:00 amRNSHemogenyx Welcomes N.Y. Lt. Governor to its Labs
7th Dec 201712:16 pmRNSResult of AGM
7th Dec 20177:00 amRNSAGM Statement
20th Nov 20177:00 amRNSUniversity of Oxford Collaboration
15th Nov 20177:00 amRNSDirectorate Change
14th Nov 20177:00 amRNSNotice of AGM
13th Nov 20174:40 pmRNSSecond Price Monitoring Extn
13th Nov 20174:35 pmRNSPrice Monitoring Extension
13th Nov 20172:05 pmRNSSecond Price Monitoring Extn
13th Nov 20172:00 pmRNSPrice Monitoring Extension
13th Nov 201711:05 amRNSSecond Price Monitoring Extn
13th Nov 201711:00 amRNSPrice Monitoring Extension
13th Nov 20179:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.